Vilon 20mg (Bioregulator)

Vilon 20mg (Bioregulator) - Overview

This is the shortest peptide, containing only two amino acids in length and based on animal research, Vilon has a significant anti-aging potential and could be a powerful immune function regulator. Some evidence suggests that this peptide could promote hemostasis and regulate the vascular system. 

Also, this peptide has been shown to reduce the size and growth of spontaneous tumors in animals, although this claim needs to be backed up by additional research. 

Chemical Structure

• Molecular formula: C11H21N3O5
• Molecular weight: 257.30g/mol
• Other known titles: Lysylglutamate, normophthal, Lysylglutamic acid

Vilon Research and Clinical Studies

Vilon and the Immune System 

Vilon is able to activate interleukin-2 signaling in cells of the spleen. Interleukin-2 is important because it coordinates immune responses and affects microbial infections while preventing immune reactions. This peptide helps restore the immune system by activating splenocytes and lymphocytes, while also strengthening the body’s natural defense against autoimmune reactions. It might even be useful in developing treatments for autoimmune conditions. 

Additionally, scientists have investigated the role of Vilon in thymus. It showed that Vilon boosted the proliferation of CD5 T-cells. CBD-5 stimulates the production of cytotoxic CD8 T-cells and mature T-helper cells. We should mention that CD8 T-cells are the body’s strongest defense against harmful microbes, while T-helper cells help regulate the immune system and keep it from attacking itself.

In simple terms, Vilon doesn’t turn lymphocytes into neurons by triggering genes that wouldn’t normally be active in healthy lymphocytes. Instead, Vilon seems to increase the activity in the immune system while at the same time helping prevent autoimmune reactions.   

Vilon and Cancer 

As mentioned previously, Vilon managed to reduce cancer cases in animals and, in some way, prolong their lifespan. Additional research in mouse models indicates that this peptide not only prevents tumors but can also prevent their growth after being diagnosed. 

This means that Vilon can be an effective chemotherapeutic and a potential addition to existing cancer treatments. In the future, based on the findings, we can expect Vilon to be a standard addition to everything, from radiation and chemo treatments to surgery. 

Moreover, one study in Russia contradicts the claim that Vilon can be successful when used together with chemo. This work shows that the combination of Vilon and chemotherapy is more problematic than beneficial. However, it’s important to mention that this used only one specific type of chemo and was limited in scope; therefore, we can’t generalize the results. In the following months and years, it remains to be seen what will happen with Vilon and whether it’s truly potent in combating cancer. 

Vilon and Anti-Aging

Studies conducted on mice indicate that Vilon administration under the skin can boost endurance and physical activity while helping to reduce the risk of cancer. These two effects led to a longer lifespan in treated mice, suggesting that this peptide could affect aging processes. The great news is that Vilon didn’t produce any side effects from long-term use. 

Another interesting thing worth mentioning is that when Vilon was administered to younger mice, it had better effects than older mice. Scientists speculate that Vilon can hardly do anything for the cells that have already been eliminated via apoptosis. When given earlier in life, this peptide has an opportunity to protect the cells and slow down turnover. It means that more cells stay healthy for longer periods of time. 

Vilon’s anti-aging effects also extend to gastrointestinal function as well. This peptide has shown remarkable results and the ability to boost the activity of certain enzymes in the GI tract of older mice. Vilon seems to enhance barrier function and minimize the cases of leaky gut in mice. Therefore, this peptide could potentially boost glycine and glucose absorption in the small intestine of older rats. 

Vilon and Heart and Kidney Health 

While the effects of Vilov on cardiovascular health haven’t been studied enough, some research suggests that this peptide may have beneficial effects. Studies conducted on mice show that Vilon can change the expression of more than 36 different genes within the heart. In combination with Epithalon, this number jumps to 144 genes. These findings suggest that Vilon may enhance hemodynamic function. 

When it comes to kidneys, clinical trials have shown that this peptide can transform the number of transforming growth factor-beta (1) and, therefore, the permeability of microvessels. The result is better homeostasis during kidney failure, meaning that this peptide truly has beneficial effects on the vascular system.  

References: 

1. Gavrisheva NA et al. (2005). Effect of Vilon on TGF-beta and microvessel permeability in chronic renal failure. Bull Exp Biol Med. 139(1):24-6. PMID: 16142267.
2. Kniaz'kin IV et al. (2002). Functional morphology of spleens exposed to Vilon. Adv Gerontol. 9:110-5. PMID: 12096432.
3. Kuznik BI et al. (2007). Effect of Vilon on immunity and coagulation in diabetes. Adv Gerontol. 20(2):106-15. PMID: 18306698.
4. Khavinson VK et al. (2000). Vilon and lifespan in mice. Bull Exp Biol Med. 130(7):687-90. PMID: 11140587.
5. Khavinson VKh et al. (2002). Vilon and enzyme activity in old rats' intestines. Bull Exp Biol Med. 134(6):562-4. PMID: 12660839.
6. Anisimov SV et al. (2002). Vilon and gene expression in mouse heart. Bull Exp Biol Med. 133(3):293-9. PMID: 12360356.
7. NCBI (2022). Lysylglutamic acid summary. Retrieved from PubChem.
8. Pliss GB et al. (2001). Vilon and rat urinary bladder tumors. Bull Exp Biol Med. 131(6):558-60. PMID: 11586406.
9. Bykov NM et al. (2002). Vilon effect on rat spleens of different ages. Adv Gerontol. 10:85-7. PMID: 12577696.
10. Khavinson VKh et al. (2000). Vilon inhibits tumors and increases lifespan in mice. Dokl Biol Sci. 372:261-3. PMID: 10944717.
11. Khavinson VKh et al. (2002). Vilon and glucose absorption in old rats. Bull Exp Biol Med. 133(5):494-6. PMID: 12420071.
12. Lezhava T et al. (2004). Vilon and chromatin reactivation in old lymphocytes. Biogerontology. 5(2):73-9. PMID: 15105581.
13. Kazakova TB et al. (2002). Vilon and interleukin-2 gene expression in splenocytes. Bull Exp Biol Med. 133(6):614-6. PMID: 12447482.
14. Barykina OP et al. (2003). Vilon and cyclophosphane in tumor transplants. Adv Gerontol. 12:128-31. PMID: 14743610.
15. Sevostianova NN et al. (2013). Immunomodulating effects of Vilon. Bull Exp Biol Med. 154(4):562-5. PMID: 23486604.
16. Kniaz'kin IV et al. (2002). Vilon and premature aging in spleen and thymus. Adv Gerontol. 9:105-9. PMID: 12096431.